No Prescription |
 |
 | ||
|
FLUANXOL Depixol |
|
| ||
No Prescription » Prescription Drugs 8 » FLUANXOL Depixol Flupenthixol is an anxiolytic antidepressive agent and a mood stabilizer. It inhibits the central monoamine receptors particularly the dopamine D1 and D2 receptors. Therefore it increases the amount of serotonin and noradrenaline that control mood and thinking and improves mood. For use in schizophrenia and depressionFlupenthixol is categorized under the following by the FDA: Antipsychotics; Thioxanthenes; Dopamine Antagonists Buy FLUANXOL Depixol and other Prescription Drugs 8 products online at Medstore. Buy Online at Medstore - Click Here!
About FLUANXOL Depixol: Product Type: Prescription Drugs 8 FLUANXOL ( Depixol Generic Flupenthixole ) FLUANXOL (Depixol Generic Flupenthixole) Depixol Generic Flupenthixole 0.5mg 1mg 200 Tablets 100 Tablets Depixol Generic Flupenthixole FLUANXOL
View more Prescription Drugs 8 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
